3619-17-8

Usage

Uses

Used in Pharmaceutical Industry:
Isobutyric acid hydrazide is used as a chemical intermediate for the production of various pharmaceuticals. Its unique chemical structure allows it to be a key component in the synthesis of drugs, contributing to the development of new medications and therapies.
Used in Organic Synthesis:
In the field of organic synthesis, isobutyric acid hydrazide is utilized as a versatile building block for the creation of a wide range of organic compounds. Its reactivity and functional groups make it an essential component in the synthesis of various chemical products.
Used in Corrosion Inhibition:
Isobutyric acid hydrazide is employed as a corrosion inhibitor in some industrial applications. Its ability to form protective layers and reduce the rate of corrosion makes it a valuable asset in protecting materials and equipment from degradation.
Used in Agricultural Chemicals Manufacturing:
In the agricultural sector, isobutyric acid hydrazide is used in the manufacturing of agricultural chemicals. Its incorporation into these products helps to enhance their effectiveness and performance in various agricultural applications.
Used as a Reagent in Analytical and Biochemical Processes:
Isobutyric acid hydrazide also serves as a reagent in certain analytical and biochemical processes. Its unique properties make it suitable for use in various laboratory techniques and assays, contributing to the advancement of scientific research and analysis.

InChI:InChI=1/C4H10N2O/c1-3(2)4(7)6-5/h3H,5H2,1-2H3,(H,6,7)

Upstream product

• 563-83-7 ISOPROPYLAMIDE 
• 97-62-1 Ethyl isobutyrate 
• 2388-01-4 methacryloyl hydrazide 
• 1523-69-9 diethyl isobutyryl phosphonate 
• 547-63-7 Methyl isobutyrate 
• 79-30-1 isobutyryl chloride 
• 79-31-2 isobutyric Acid 

Downstream Products

• 857800-87-4 isobutyric acid-(N'-trityl-hydrazide) 
• 146659-61-2 (E)-N'-(2-hydroxybenzylidene)isobutyrohydrazide 
• 121936-73-0 isobutyric acid-(1-methyl-2-oxo-propylidenehydrazide) 
• 79-30-1 isobutyryl chloride 
• 26090-75-5 Isobutyric acid [1-(4-chloro-phenyl)-meth-(E)-ylidene]-hydrazide 
• 25996-87-6 Isobutyric acid [1-(4-chloro-phenyl)-eth-(Z)-ylidene]-hydrazide 
• 25996-52-5 Isobutyric acid [1-(2,4-dichloro-phenyl)-meth-(Z)-ylidene]-hydrazide 
• 26090-78-8 Isobutyric acid [1-(4-bromo-phenyl)-meth-(E)-ylidene]-hydrazide 
• 138793-95-0 4-(1-Hydroxy-naphthalen-2-yl)-3-(N'-isobutyryl-hydrazinocarbonyl)-6-(4-methoxy-phenyl)-cyclohex-4-ene-1,2-dicarboxylic acid 
• 124614-79-5 1-(2-methylpropanoyl)-2-(3-methyl-2-butylidene)hydrazine 
• 133662-15-4 Isobutyric acid [1-(2-chloro-phenyl)-eth-(E)-ylidene]-hydrazide 
• 120571-99-5 N-[(E)-1-(3-Isopropyl-[1,2,4]triazolo[4,3-c]quinazolin-5-yl)-2-(4-methoxy-phenyl)-vinyl]-benzamide 
• 120571-94-0 2-Chloro-N-[(E)-1-[2-(N'-isobutyryl-hydrazinocarbonyl)-phenylcarbamoyl]-2-(4-methoxy-phenyl)-vinyl]-benzamide 
• 128153-96-8 Isobutyric acid [1-(2,4-dichloro-phenyl)-eth-(E)-ylidene]-hydrazide 

Relevant academic research and scientific papers

Synthetic method of 1,3,4-thiadiazole derivative

The invention discloses a synthetic method of a 1,3,4-thiadiazole derivative. The method comprises the following steps: (1) using hydrazine hydrate as a raw material, under the action of a catalyst, reacting with acid, to obtain a hydrazide compound I; (2) using alkyl chloroformate and thiocyanate to react in a condition of a solvent, to obtain an isothiocyanate compound II; (3) in a reaction system of the isothiocyanate compound II, adding solution containing the compound I, reacting to obtain solution containing a compound III; (4) processing the solution of the compound III by dehydrating,neutralizing, and washing, to obtain a compound IV; (5) in the conditions of an acid-binding agent and a solvent, adding alkyl halide or sulfuric acid diester into the compound IV, reacting to obtaina compound V; and (6) enabling the compound V to perform an amination reaction with primary amine, to obtain the 1,3,4-thiadiazole derivative VI. The preparation method has the advantages of green andno pollution, simple and convenient operation, higher yield, mild reaction condition and the like.

Method for preparing 3-isopropyl-4-amino-1,2,4-triazoline-5-ketone

The invention discloses a method for preparing 3-isopropyl-4-amino-1,2,4-triazoline-5-ketone. The method comprises the following steps: 1, reacting isobutyric acid and hydrazine hydrate in an n-butylalcohol solvent at the reaction temperature of 50-150 DEG C, and producing isobutyrohydrazide; 2, reacting the isobutyrohydrazide synthesized in the step 1 and phosgene or solid light and the n-butylalcohol serving as the solvent at the reaction temperature of 0-60 DEG C, and producing 2-isobutyl hydrazino-butyl formate; 3, reacting the 2-isobutyl hydrazino-butyl formate synthesized in the step 2with hydrazine hydrate in aqueous alkali at a reaction temperature of 80-120 DEG C, thereby obtaining the 3-isopropyl-4-amino-1,2,4-triazoline-5-ketone and n-butyl alcohol. According to the method disclosed by the invention, single n-butyl alcohol serves as the solvent in the whole reaction process, the intermediate process is not separated, and the method has the advantages of being simple in reaction system, high in reaction speed and less in amount of three wastes; the n-butyl alcohol can be repeatedly used; and the synthetic method has the yield of 85%.

COMPOUNDS AS HEPATITIS C INHIBITORS AND USES THEREOF IN MEDICINE

Provided herein are compounds as hepatitis C inhibitors and uses thereof in medicine. Specifically, provided herein is a compound of Formula (I) or a stereoisomer, a tautomer, an enantiomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or hepatitis C diseases. Also provided herein are a pharmaceutically acceptable composition containing such compound and a method of treating HCV infection or hepatitis C diseases comprising administering the compound or pharmaceutical composition thereof disclosed herein.

Arylazolylthioacetanilide. Part 11: Design, synthesis and biological evaluation of 1,2,4-triazole thioacetanilide derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors

A series of novel 1,2,4-triazole thioacetanilide derivatives has been designed, synthesized and evaluated for their anti-HIV activities in MT-4 cells. Half of these compounds showed moderate to potent activities against wild-type HIV-1 with an EC50 ranging from 38.0 μM to 4.08 μM. Among them, 2-(4-(2-fluorobenzyl)-5-isopropyl-4H-1,2,4-triazol-3-ylthio)-N-(2-nitrophenyl) acetamide 7d was identified as the most promising compound (EC50 = 4.26 μM, SI = 49). However, no compound was active against HIV-2. The preliminary structure-activity relationships among the newly synthesized congeners are discussed.

INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS

This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.

ORGANOMETALLIC COMPLEX, LIGHT-EMITTING ELEMENT, DISPLAY DEVICE, ELECTRONIC DEVICE, AND LIGHTING DEVICE

Provided are organometallic complexes that can exhibit phosphorescence. One of the novel organometallic complexes is represented by General Formula (G1). In General Formula (G1), R1 represents any of an alkyl group having 1 to 6 carbon atoms, a cycloalkyl group having 5 to 8 carbon atoms which may have a substituent, and an aralkyl group having 7 to 10 carbon atoms which may have a substituent. In addition, R2 represents any of an alkyl group having 1 to 6 carbon atoms, a cycloalkyl group having 5 to 8 carbon atoms which may have a substituent, and an aryl group having 6 to 12 carbon atoms which may have a substituent. Further, Ar represents an arylene group having 6 to 13 carbon atoms which may have a substituent. Further, M represents a Group 9 element or a Group 10 element.

INHIBITORS OF AKT ACTIVITY

The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.

INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS

Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

Keto-1,3,4-oxadiazoles as cathepsin K inhibitors

We have prepared a series of cathepsin K inhibitors bearing the keto-1,3,4-oxadiazole warhead capable of forming a hemithioketal complex with the target enzyme. By modifying binding moieties at the P1, P2, and prime side positions of the inhibitors, we have achieved selectivity over cathepsins B, L, and S, and have achieved sub-nanomolar potency against cathepsin K. This series thus represents a promising chemotype that could be used in diseases implicated by imbalances in cathepsin K activity such as osteoporosis.